HIFU, or high-intensity focused ultrasound, is a minimally invasive treatment for prostate cancer that uses concentrated sound waves to heat and destroy cancerous tissue. Rather than removing the prostate surgically, HIFU targets specific areas of the gland while leaving surrounding healthy tissue intact. It’s primarily used for localized, early-stage prostate cancer and is gaining traction as an alternative to surgery and radiation for select patients.
How HIFU Works
HIFU works by focusing ultrasound energy, much like a magnifying glass focuses sunlight, onto a precise spot inside the prostate. The focused beam generates intense heat within a target zone just millimeters wide, causing what’s called coagulative necrosis: the cancer cells are essentially cooked and die. The surrounding tissue, because it falls outside the focal point, remains largely unharmed.
The ultrasound probe is inserted through the rectum and guided by real-time imaging, typically MRI fused with ultrasound. This allows the treating physician to map the tumor’s exact location and shape the treatment zone accordingly. The procedure takes roughly 3 to 3.5 hours under general or spinal anesthesia, and most patients go home the same day or the next morning.
Focal Therapy vs. Whole-Gland Treatment
HIFU can be delivered in two ways. Focal therapy treats only the tumor and a small margin around it, preserving most of the prostate. Whole-gland therapy ablates the entire prostate, similar in scope to surgery but without incisions. Focal therapy is the more common modern approach because it dramatically reduces side effects. In studies comparing the two, men who received focal HIFU maintained significantly better erectile function scores at both 3 and 12 months after treatment. Focal therapy patients also had far better urinary continence, with a 90% lower chance of needing pads compared to men who underwent radical surgery.
Who Qualifies for HIFU
HIFU is not an option for every prostate cancer diagnosis. It works best for cancer that hasn’t spread beyond the prostate itself. The typical eligibility criteria include:
- Tumor stage T2 or lower (cancer confined to the prostate)
- A visible tumor on MRI that measures less than 20 mm across
- Tumor location within 40 mm of the rectal wall, so the ultrasound probe can reach it effectively
- No Gleason pattern 5 on biopsy (meaning the most aggressive grade of cancer cells is absent)
- PSA level of 20 ng/mL or lower
Men between 40 and 80 are generally considered candidates. If your cancer is higher-risk, has spread to lymph nodes, or shows the most aggressive cell patterns, your care team will typically recommend surgery or radiation instead.
What Recovery Looks Like
Recovery from HIFU is considerably faster than from surgery. Most men spend just one night in the hospital, and many leave the same day. A urinary catheter is placed at the end of the procedure and stays in for 3 to 4 days while swelling subsides. After the catheter comes out, you’ll do a trial to confirm you can urinate normally on your own.
Most men return to normal daily activities within a week or two. There’s no surgical incision to heal, no stitches, and no drain tubes. Mild discomfort in the rectal area and some blood in the urine are common in the first few days but resolve quickly.
How Effective Is HIFU
A large multicentre study tracking patients for a median of nearly 5 years found strong survival numbers. Cancer-specific survival at 5 years was 100%, and overall survival was 99%. Metastasis-free survival, meaning cancer had not spread to distant sites, was 98%. Failure-free survival, which accounts for any sign of cancer recurrence, was 88% overall: 96% for low-risk patients, 88% for intermediate-risk, and 84% for high-risk.
These numbers are encouraging, but they come with context. When directly compared to laparoscopic radical prostatectomy (surgical removal of the prostate) in one study, HIFU focal therapy showed higher rates of treatment failure. About a third of HIFU patients had either a rising PSA or a positive follow-up biopsy, compared to none in the surgery group. HIFU was inferior to surgery for cancer control in that comparison. The tradeoff is functional: HIFU patients kept their continence and erectile function at significantly higher rates.
This tradeoff is central to the HIFU decision. It offers a gentler treatment with better quality of life outcomes, but with a higher chance that some cancer may persist or return. If cancer does recur after HIFU, the procedure can often be repeated, or patients can move to surgery or radiation as a next step.
Side Effects
HIFU’s side effect profile is milder than surgery or radiation, but it’s not zero-risk. The most studied side effects are erectile dysfunction and urinary problems.
For erectile function, one study found that 36% of men experienced severe erectile dysfunction 12 months after focal HIFU. That’s a meaningful number, though it’s substantially lower than rates seen after radical prostatectomy. Men who had focal therapy retained better erectile function scores at every follow-up point compared to men who had whole-gland treatment or surgery.
Urinary incontinence is uncommon after focal HIFU. In comparative studies, HIFU patients used far fewer pads and were much more likely to be fully continent than men who had their prostate removed. Other possible side effects include urinary tract infections, temporary difficulty urinating, and, rarely, a connection forming between the rectum and urinary tract (a fistula), though this complication has become increasingly rare with modern devices.
Insurance and Cost Considerations
Coverage for HIFU in the United States remains inconsistent. There is no national Medicare coverage determination for the procedure, which means individual regional Medicare carriers decide on a case-by-case basis whether to reimburse it. Some private insurers classify HIFU as experimental or investigational and decline coverage. The Federal Employees Program (Blue Cross Blue Shield), for example, currently considers focal therapies for prostate cancer, including HIFU, not medically necessary under their policy.
Out-of-pocket costs for HIFU can range from $15,000 to $25,000 or more depending on the facility and region. Some specialized centers offer financing or can help navigate insurance appeals. If you’re considering HIFU, it’s worth contacting both your insurer and the treatment center early to understand your financial responsibility before committing to the procedure.